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ABSTRACT 
 
Introduction: Circulating tumor cells (CTCs) are cells originating from 
primary and/or metastatic tumor and circulating freely in the peripheral blood 
of cancer patients. CTCs can serve as a liquid biopsy for real time monitoring 
of disease progression and therapy efficacy. Due to CTCs rarity in the blood 
and the lack of strategies to isolate CTCs entire heterogeneous population, 
CTCs phenotype has not been fully defined. Commonly used epithelial 
markers-based isolation approaches failed in detecting epithelial mesenchymal 
(EMT) transitioned CTCs. The purpose of this study was to isolate and 
characterize the entire population of viable CTCs from metastatic breast cancer 
(MBC) patients. 
Methods: Peripheral blood samples from 44 locally advanced and MBC 
patients and 4 healthy donors (HD) were collected in this study. In the first part 
of the study we isolated CTCs from blood samples of 14 MBC patients through 
an antibody-mediated enrichment procedure (RosetteSepTM). Then, freshly 
isolated CTCs from 8 samples were analyzed by immunofluorescence (IF), 
whereas isolated cells from 6 samples were seeded on cover glass. In the 
second part of the study we isolated circulating cells from 30 MBC samples 
and 4 HD by using Ficoll density gradient followed by the seeding of free 
labeled PBMCs on cover glass. In 6/30 samples mRNA expression levels of 
CD45, ERα, HER2, CK19 and Vimentin were evaluated by qRT-PCR for both 
PBMCs and adherent cells. Furthermore, IF experiments were performed on 
adherent isolated cells, and on samples collected after three months of therapy, 
for testing the presence of ERα, HER2 and different EMT markers. 
Results: CTCs isolated by RosetteSepTM protocol stained positive only for the 
mesenchymal marker Vimentin, and RosetteSepTM seemed to affect the 
adherence ability of circulating cells. Interestingly, adherent cells isolated by 
Ficoll stratification showed reduced mRNA levels of leukocyte marker CD45 
and higher mRNA levels of CK19 and Vimentin than PBMCs. Also, Vimentin 
and CK19 proteins were the most representative markers in adherent cells 
fraction. Furthermore, therapy reduced the number of CD45- cells and affected 
the number of different adherent cells subpopulations. 
Conclusions: We established a label-free method for the isolation and 
characterization of circulating cells in MBC, which allowed the depletion of 
most contaminating leukocytes and the enrichment of circulating cells 
expressing epithelial and mesenchymal markers. Heterogeneity of adherent 
cells underlined the importance of further characterize these cells to understand 
more about their role in metastatic disease and to improve personalized 
therapeutic approaches. 
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Abbreviations 
 
CTCs                  Circulating tumor cells 
CK5                    cytokeratin 5 
CK18                  cytokeratin 18 
CK19                  cytokeratin 19 
EGFR                 Epithelial growth factor receptor 
EMT                   Epithelial Mesenchymal Transition 
EpCAM              Epithelial cell adhesion molecule 
ER                       estrogen receptor 
HD                      healthy donors 
HER2                  epidermal growth factor receptor 2 
IF                        immunofluorescence 
MBC                   metastatic breast cancer 
OS                       overall survival 
PBMCs               Peripheral blood mononuclear cells 
PFS                     progression free survival  
PR                       progesterone receptor 
RBCs                  red blood cells 
TNBC                 triple negative breast cancer 
WBCs                 white blood cells 
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1. INTRODUCTION 
 
1.1 Breast cancer: epidemiological data and risk factors 
Breast cancer is the second most common cancer for both sexes combined, 
preceded only by lung cancer. Among women, breast cancer is the most 
frequently diagnosed cancer with 2,1 million newly diagnosed cancer cases in 
2018 (Bray et al. 2018). Also, it represents the leading cause of cancer death 
among females in over 100 countries.  Breast cancer incidence rate is highest 
in Australia/ New Zeeland, Western and Northern Europe, Northern America, 
Southern Europe; however, mortality rate compared to incidence is higher in 
less developed regions, such as Middle / Western Africa and South-Central 
Asia, than in more developed ones (figure1). This trend relies on different 
factors related to social and economic development: having few children, 
obesity, sedentary lifestyle, breast cancer screening and awareness. Indeed, 
inherited mutations (BRCA1, BRCA2, and other breast cancer susceptibility 
genes) are responsible for only the 5-10% of breast cancer cases, whereas non-
hereditary factors are the main drivers of observed differences in incidence rate 
among countries (Bray et al. 2018). Non- hereditary risks factors for breast 
cancer developing include long exposure to estrogen hormones (early 
menarche, late menopause, nulliparity, late age at first birth, few children) and 
nutrition (alcohol intake, high fat diet, high weight). On the contrary, low fat 
diet, breastfeeding and physical activity are considered protective factors 
(Falkenberry and Legare 2002). 
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Figure 1. Bar chart of region-specific incidence and mortality for breast cancer 
in 2018 (Bray et al. 2018). 
 
1.2 Breast cancer molecular subtypes and standard therapies 
Breast cancer is a highly heterogeneous disease, which is commonly classified 
in noninvasive or in-situ carcinoma, confined to the ducts and lobules, and 
infiltrating or invasive carcinoma, in which malignant cells have penetrated 
through the duct wall into the stroma. In addition, both in-situ and invasive 
breast carcinomas are defined as ductal or lobular depending on the site of 
origin of tumor cells. In the last decades, the improving of gene profiling 
techniques have been allowed a molecular classification of breast tumors based 
on the expression of hormones receptors, estrogen receptor (ER) and 
progesterone receptor (PR), and the low expression or amplification of human 
epidermal growth factor receptor 2 (HER2) gene (Perou et al. 2000). 
Importantly, this molecular classification of breast tumors is fundamental for 
therapeutic planning. Indeed, there are four molecular breast cancer subtypes: 
Luminal A, Luminal B, HER2 positive and Basal like, that are treated with 
specific therapies. 
Luminal A is ER/PR positive, and it accounts for 50% of breast cancers. The 
Luminal B subtype, representing the 20% of invasive breast tumors, is positive 
for ER/PR and HER2, has a proliferative index rate (Ki67) and a histological 
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grade higher than Luminal A. HER2 positive subtype accounts for the 15% of 
invasive breast cancers overexpress HER2; this subtype is characterized by 
high Ki67 and commonly shows TP53 mutations. The basal like breast cancers, 
also named triple negative, show a pattern of expression similar to mammary 
basal epithelial cells and myoepithelial cells. They are ER/PR and HER2 
negative, typically express cytokeratins 5/6 (CK5/6) and/or epithelial growth 
factor receptor (EGFR), have high Ki67 and are frequently TP53 mutated. This 
last group comprises about 15% of invasive breast tumors and has in general 
poor prognosis. 
Molecular classification of breast cancer subtypes has helped in defining type 
specific targeted therapy. 
Estrogen dependent breast cancers (Luminal subtypes) are treated with 
inhibitors of the estrogen signaling pathway, such as Tamoxifen. Tamoxifen, 
a selective estrogen receptor modulators (SERM), is the first approved drug 
for the treatment of estrogen positive metastatic breast cancer; it reduced 
recurrence by approximately 40%-50%. In menopausal and post- menopausal 
women, the estrogen signaling pathway is sustained by aromatase enzyme 
activity, which consists in synthesizing estrogens by using androgen hormones 
as a substrate. Aromatase inhibitors (anastrozole, letrozole, exemestane) are 
the elective therapy for this condition (den Hollander et al. 2013). 
As estrogen inhibitor are the best choice for estrogens-drived cancer subtypes, 
the inhibition of HER2 signaling represents the therapeutic goal in HER2 
overexpressing breast tumors. In 1998 the FDA approved the first drug for the 
treatment of HER2 positive breast cancers, the recombinant antibody 
trastuzumab (Herceptin) (Pegram et al. 1998). Since then, other agents have 
been approved, pertuzumab (HER2 inhibitor) and lapatinib (tyrosine kinase 
inhibitor). In 2013 a boosted version of trastuzumab was approved by FDA for 
the treatment of HER2 positive breast tumors, the conjugated monoclonal 
antibody TDM1 (trastuzumab emtansine). TDM1 efficiently vehicles the DM1 
drug, a microtubule inhibitor, directly into HER2 positive breast cancer cells 
to inhibit their growth (Verma et al. 2012). 
Triple negative breast cancers (TNBC), which lack hormone receptors and 
HER2, are conventionally treated by using taxol derivatives and anthracycline 
chemotherapy. 
Besides that, some patients have tumors whose cancer cells overexpress 
specific proteins, which are fundamental to drive tumor growth. Moreover, 
there are several drugs targeting these molecules that represent useful tools for 
breast cancer cure.  Everolimus (Afinitor), a m-TOR inhibitor, stops cancer 
cells from getting energy supply (Steelman et al. 2016), and bevacizumab 
(Avastin), that acts against the vascular endothelial growth factor (VEGF), 
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which stimulates the formation of new blood vessels, necessary for the filling 
of oxygen and nutrients (den Hollander et al. 2013). 
Despite the big effort in tumor classification and in the development of breast 
cancer subtype targeted therapy, the 25% of breast cancer patients relapse and 
about 10-15% of patients develop an aggressive disease with distant metastases 
within 5 years after diagnosis (Colzani et al. 2014). 
 
1.3 Metastatic breast cancer 
Metastatic breast cancer is a pathological condition in which cancer cells have 
spread from primary tumor toward distant sites to form secondary tumor, also 
named metastasis. Metastasis is the main cause of cancer related death. Indeed, 
breast cancer metastases can occur even ten years after the removal of primary 
tumor. The common sites of metastases in breast cancer are lymph nodes, bone, 
liver, lung and brain, but breast cancer can give rise to metastasis at almost any 
sites. Nowadays the molecular profiling of the primary tumor has helped in 
designing personalized therapy, and metastatic breast cancer is treated with a 
combination of chemotherapy and targeted therapy according with the 
molecular subtype of the primary tumor. Unfortunately, many patients do not 
respond to systemic treatment due to molecular heterogeneity and dynamic 
nature of the tumor. Although dissecting the molecular basis of metastasis 
formation has been the main goal of many research groups in the last decades, 
how cancer cells acquire the metastatic traits remain unknown. 
The metastatic cascade is a very complex biological process and different 
theories about metastasis development have been proposed. The theory of 
clonal evolution of cancer supports the idea that metastasis arises from the 
clonal expansion of preexisting variant cancer cells within the primary tumor 
mass (Fidler and Kripke 1977). In 2006 Hess and collaborators proposed that 
drivers mutations confer the metastatic ability to cancer cells (Hess et al. 2006). 
Besides the need of a metastatic genetic trait, the “seed and soil” theory, 
enunciated by Paget in 19th century, introduced the relationship between cancer 
cells and microenvironment (Paget 1889). Paget affirmed that cancer cells seed 
metastasis only when they reach a proper microenvironment. Furthermore, 
there are evidences in the literature that partially support all these theories, 
making metastasis formation a very articulated process. Indeed, many cancer 
cells can be released from the bulk of primary tumor, but only few of them are 
capable to generate metastasis (Gupta and Massagué 2006) (Fidler 2003). 
To form clinically detectable metastasis, cancer cells must invade the 
neighboring tissues, entry and survive into the circulation, arrest at secondary 
site, where they have extravasate and colonize the new region. Once metastatic 
cells have colonized the secondary organ, they can proliferate to form 
detectable macrometastasis or, they can form undetectable micrometastasis 
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remaining in a latent state also for years (Vanharanta and Massagué 2013) 
(figure2). 
To face the metastatic cascade, cancer cells need to change their phenotype 
from a static epithelial to an invasive and migratory one. This occurs because 
of a biological process called epithelial mesenchymal transition (EMT).  
Epithelial Mesenchymal Transition, a well-known process involved in 
embryonic development, wound healing and tissue regeneration, represents a 
hallmark in metastasis formation and correlates with the acquiring of stem-like 
features and poorly differentiated phenotype (Micalizzi et al. 2010). During 
EMT epithelial cells lose cell polarity and cell adhesion and gain invasive and 
migratory properties. Also, epithelial mesenchymal transitioned cells become 
resistance to anoikis, substrate-dependent apoptosis, allowing them to survive 
in the circulation. Generally, cells that have undergone EMT lose or express 
low levels of epithelial markers, such as cytokeratins 18 (CK18), cytokeratin 
19 (CK19), EpCAM and E-Cadherin and express mesenchymal markers, such 
as N-Cadherin, Alpha-SMA, β-catenin and Vimentin. All these changes are 
orchestrated by the activation of genetic signatures regulated by specific 
transcription factors: Snail1, Snail2, Twist, EF1/ZEB1, SIP1/ZEB2 and E47 
(Craene and Berx 2013). 
Carcinoma cells that have disseminated to distant tissues can persist at the 
secondary site for a long time as dormant disseminated tumor cells (DTCs), 
without giving metastasis; because of signaling pathways that sustain DTCs 
quiescence and survival. The microenvironment contributes to these events, by 
releasing mediators such as CXCL12 (C-X-C motif chemokine 12), which 
promotes the activation of SRC and AKT survival pathway in DTCs, or by 
releasing bone morphogenetic proteins (BMP4/7), which enacts a quiescent 
program in DTCs that is associated with an ERKlow/p38high signaling state. 
DTCs dormancy is promoted also by thrombospondin-1 (TSP1), which is 
present in the basement membrane of blood vessels. Moreover, dormant cells 
can repress natural killer cell-activating ligand, thus evading NK cells 
detection (Lambert et al. 2017). The latent state of cancer cells is the 
responsible for late recurrence in breast cancer. 
Blocking the metastatic cascade is fundamental to fight cancer progression. In 
this scenario, understanding the biology of circulating cancer cells could be the 
answer to many open questions about the metastatic process and would help in 
the clinical management of tumor progression. 
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Figure 2. Steps for metastasis formation (Vanharanta and Massagué 2013). 
 
 
1.4 Circulating Tumor Cells (CTCs) 
Circulating tumor cells (CTCs) are cancer cells, that originate from primary 
and/or metastatic tumor and circulate freely in the peripheral blood of cancer 
patients (Allard 2004). It has been shown that CTCs resemble cancer stem 
cells, in terms of self-renewal, tumor initiation capability and invasion at the 
single cell level (Aktas et al. 2009). Importantly, CTCs are considered the 
responsible of distant metastasis (figure3). Thus, the study of CTCs could 
elucidate the molecular basis of metastasis formation and tumor progression. 
Moreover, CTCs can be found in the bloodstream, thus their sampling can be 
considered as a “liquid biopsy”, a noninvasive procedure to monitor cancer 
progression and therapy efficacy. 
Importantly, the presence of CTCs in MBC patients has a significant 
prognostic impact regardless the subtype of breast tumors. Indeed, CTCs count 
in MBC patients independently predicts progression free survival (PFS) and 
overall survival (OS). 
The first evidence about the prognostic value of CTCs were provided by 
Cristofanilli et al; they found that patients with CTCs number higher than 5 
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cells per 7,5 mL of blood had a bad prognosis, evaluated by PFS and OS 
(Cristofanilli et al. 2004).  
 
 
Figure 3. CTCs mediated metastatic cascade (Pantel and Speicher 2015). 
 
Then, the same cut off has been confirmed also by other studies (Hayes et al. 
2006; Dawood et al. 2008). Moreover, baseline CTCs number is a predictive 
marker in patients receiving different type of first-line systemic treatment 
(Giuliano et al. 2011). Also, many studies have investigated the prognostic 
value of CTC number, in MBC patients, depending on the subtype of primary 
tumor. Two studies underlined the prognostic value of CTCs, except for 
patients with HER2 overexpressing tumors treated with HER2 targeted 
therapies; thus, it was hypothesized that anti-HER2 treatments eliminate CTCs 
that freely circulated in the blood of breast cancer patients (Giordano et al. 
2012; Pierga et al. 2012). In effect, a large prospective multicenter study, in 
which only 6,5% of patients received anti-HER2 based therapies, 
demonstrated the prognostic value of CTCs independently from primary tumor 
subtype (Wallwiener et al. 2015). Besides the metastatic disease, CTCs 
enumeration has an important impact also in the prognosis of non-invasive 
breast cancer. In fact, CTCs were detected also in peripheral blood of early 
breast cancer patients. In a large study conducted by the German SUCCESS 
study group (EUDRA-CT No.2005-000490-21, NCT02181101), about 22% of 
early breast cancer patients had CTCs in their blood. Although all tested cut 
off ( from 0 to more than 5 CTCs in 30 mL of blood) showed a significant 
impact on patients outcome, the prognosis deteriorated continuously with 
increasing CTCs number (Rack et al. 2014). Indeed, in patients with primary 
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breast cancer, who have undergone neoadjuvant or adjuvant therapy, CTCs 
detection is a prognostic factor for early relapse (Nakagawa et al. 2007; Pierga 
et al. 2008) (Bidard et al. 2013). All these data underline the importance of 
CTCs count for monitoring the status of disease in both early and metastatic 
breast cancer. Despite that, to improve CTCs clinical utility and to develop 
CTCs based personalized treatment, the enumeration of these cells is not 
enough. Instead, a complete characterization of CTCs is needed. 
Considering CTCs rarity in the blood (1-100 CTCs per 10 9 blood cells), and 
the lack of unique specific markers to identify them, the isolation of CTCs 
represents an additional challenge for their molecular characterization. In the 
last decade many efforts have been focused on the development of techniques 
to efficiently isolate and characterize CTCs. 
CTCs enrichment methods are divided in non-affinity and affinity-based 
technologies. 
Non-affinity isolation strategies distinguish CTCs from surrounding 
hematopoietic cells according to their physical (size, electric charge, 
deformability) characteristics. Among these CTCs enrichment techniques, 
there are methods, such as ISET® (Rarecells, France), ScreenCell® (ScreenCell, 
France) and CellSieve (Creatv Microtech, USA), that select CTCs by size-
based filtration (Desitter et al. 2011; Adams, Zhu, et al. 2014). Indeed, CTCs 
have a diameter of 15-25µm, whereas red blood cells and white blood cells 
measures 5-7µm and 7-15µm of diameters, respectively. These techniques 
have low sensitivity and specificity, because CTCs are a heterogeneous 
population; therefore, small CTCs can pass through the filters, while big 
leukocytes can be trapped, contaminating the sample. 
Density gradient centrifugation separates mononuclear cells from other blood 
cells. When stratified over Ficoll medium cells migrate in different layers 
according to their density (BOYUM et al. 1991). Despite the contamination by 
mononuclear leukocytes, this method allows the isolation of a broad population 
of viable CTCs. 
Microfluidic techniques take advantages of physical and biological qualities of 
CTCs. The most representative of this group are DEPArrayTM (Menarini 
Silicon Biosystem, ITA) and CTC ichip. The DEPArrayTM identify desired 
cells by staining them for selected markers; cells are then trapped in cages by 
using an electric field (dielectrophoresis). The monolithic CTC ichip combines 
the depletion of leukocytes, by using antibodies targeting CD45, CD16 and 
CD66b, with a cell sorting system based on cell size (Fachin et al. 2017). 
The affinity-based technologies isolate CTCs by using markers that are not 
present in normal blood cells. Among these strategies, the most used is the 
CellSearch System® (Veridex, USA), which consists in ferrofluidic beads 
coated with an antibody against the epithelial cells adhesion molecule 
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(EpCAM) for the enrichment of epithelial cells. CTCs are identified as 
nucleated cells (DAPI positive staining), expressing cytokeratins 8, 18, 19, and 
negative for leukocyte common antigen CD45. The analysis results are 
presented as number of cells per 7,5 mL of blood. CellSearch® allows the 
isolation of EpCAM positive circulating epithelial cells, losing circulating cells 
that do not express EpCAM. Indeed, it has been broadly described that 
epithelial markers, especially EpCAM, are often lost or downregulated during 
tumor progression. Despite that, so far, the CellSearch® system remains the 
only method approved by the Food and Drug Administration (FDA) for the 
enumeration of CTCs in solid tumors (Allard 2004; Cristofanilli et al. 2004). 
Another affinity-based method to isolate CTCs is the AdnaTest (AdnaGen AG, 
Germany). It enriches CTCs by using magnetic beads coated with anti-EpCAM 
antibodies, then isolated labeled cells are subjected to multiplex RT-PCR to 
evaluate the expression of tumor specific markers: GA773-2, MUC-1 and 
HER2 (Andreopoulou et al. 2012). 
Affinity based technologies include also depletion methods such as EasySepTM 
and RosetteSepTM depletion kit. Easy Sep kit (StemCell Technologies, CA) 
uses CD45 antibodies bound to magnetic beads and depletes white blood cells 
(WBCs) by using a magnetic field (Yang et al. 2009). RosetteSepTM  kit 
(StemCell Technologies, CA) combines Ficoll density gradient with antibody-
mediated depletion of white blood cells (WBCs) and red blood cells (RBCs) 
(Naume et al. 2004). 
Although many companies have invested in the development of innovative 
strategies to isolate CTCs, currently a method to efficiently enrich the whole 
population of CTCs from cancer blood samples do not yet exists. This failure 
relies on the highly heterogeneity of circulating cells, indeed a unique marker 
that is present only on CTCs and is shared from the entire population of CTCs 
has not been identified so far. Thus, research community has been focusing in 
a wide characterization of CTCs to find a panel of markers that can be used as 
CTCs signature for an efficient isolation and an extensive study of these cells. 
It has been demonstrated that CTCs express low levels of E-cadherin and high 
levels of N-cadherin, as expected for their status of circulating cells. Regarding 
CTCs heterogeneity, it has been found that they can express both epithelial and 
mesenchymal markers (Yu, Bardia, Ben S. Wittner, et al. 2013). The most 
studied epithelial markers are EpCAM and cytokeratins (CK8, CK18, CK19), 
whereas the most observed mesenchymal markers are Vimentin and 
fibronectin. Furthermore, CTCs resemble cancer stem cells in the expression 
of stemness markers such as CD44, NOTCH1 and ALDH1 (aldehyde 
dehydrogenase) (Papadaki et al. 2014).  Also, proteins involved in pathways 
that sustain migration and survival such as EGFR, PI3K/AKT signaling 
molecules are expressed in CTCs of breast cancer patients (Kallergi et al. 
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2008). Moreover, it has been proposed that CTCs chemotherapy resistance is 
due to the pre-activation status of checkpoints protein complexes that allow a 
faster DNA damage response (Gong et al. 2015) . In addition, EMT and stem 
like phenotype described for CTCs are themselves related to chemoresistance 
(Mitra et al. 2015). Thus, a better characterization of these cells to find CTCs 
specific druggable targets needs to be addressed. 
The characterization of CTCs is an exciting challenge; as tumor mass is 
composed by different cancer cells clones, then CTCs consists in different 
circulating subpopulations of tumor cells. Interestingly, it has been proposed 
that the identification and molecular profiling of CTCs subpopulations could 
help not only in simply predict tumor progression but also the site of future 
metastasis. In addition, a subpopulation of breast cancer CTCs competent for 
brain metastasis, characterized by the specific signature 
HER2+/EGFR+/HPSE+/Notch1+ ,  have been recently identified (Zhang et al. 
2013; Boral et al. 2017) 
It has been reported that CTCs can circulate in the blood as single cells and 
clusters. It has been demonstrated in a mammary tumor mouse model that 
CTCs clusters originate from the bulk of primary tumor, they are enriched of 
plakoglobin and have higher metastatic potential than single CTCs (Aceto et 
al. 2014). Additionally, the interactions that CTCs may have in the 
bloodstream and at the final site of extravasation could influence their behavior 
and affect the formation of metastasis. CTCs are found in the blood also in 
cluster with leukocytes. It seems that CTCs interact with circulating 
macrophages in the bloodstream, and it has been proposed that those 
macrophages can help tumor cells to reach distant metastatic sites (Adams, 
Martin, et al. 2014). Additional studies are needed to better define the 
interactions between CTCs and blood cells in order to reveal whether these 
interactions can affect metastatic process. 
Together these data build a scenario in which the study of CTCs is a crucial 
opportunity for more understanding the biology of metastatic disease and for 
improving cancer management in general.  
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2. AIM 
 
Despite recently advances in personalized targeted cancer therapy, 25% of 
breast cancer patients relapse and about 10-15% of patients develop an 
aggressive disease with distant metastases within 5 years after diagnosis. 
Therapeutic failure mainly relies on breast cancer heterogeneity both at the 
beginning of disease and during its progression. The changes that occur during 
progression are driven by different subpopulation of cancer cells.  Hence, 
sampling the tumor at multiple time points to analyze cancer cells 
subpopulations would guide clinicians in planning personalized treatments 
based on time and stage-dependent tumor characteristics.  
CTCs are considered the responsible for the formation of distant metastasis; 
they are cancer cells originating from primary and/or metastatic tumor and 
circulating freely in the peripheral blood of cancer patients.  The analysis of 
CTCs isolated from peripheral blood samples represents a non-invasive 
procedure that could be routinely conducted to monitor “in real time” disease 
progression and therapy efficacy. Despite this promising evidence, the use of 
CTCs in the clinical practice is still limited. Indeed, their rarity in the blood (1 
CTC in 106-107 leukocytes) and the lack of strategies to isolate the whole CTCs 
heterogeneous population make their phenotyping a technological challenge. 
In addition, mainly CTCs isolation methods are epithelial marker-based 
approaches, which fail in detecting circulating cells with mesenchymal 
features. Then, a better understanding of CTCs population through an 
improvement of isolation procedures, and an extensive characterization are 
required. 
In this thesis, we aim to address this need by characterizing MBC circulating 
cells isolated through non-epithelial-based strategies. Isolated cells features 
were uncovered by qRT-PCR and a more extensive characterization was 
conducted by IF. Furthermore, IF experiments were performed also on samples 
collected after three months of therapy, to enlighten changes eventually 
occurred in circulating cells subpopulations.  
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3. MATERIALS AND METHODS 
 
3.1 Cell cultures 
The breast cancer cell lines MCF-7, MDA- MB-231 (MDA) and BT474 were 
obtained from the American Type Culture Collection (ATCC; Manassas, VA, 
USA). Cells were grown in standard medium DMEM (Sigma-Aldrich, USA) 
supplemented with 2mM glutamine (Sigma-Aldrich, USA), 1% 
penicillin/streptomycin (Life Technologies, Carlsbad, CA, USA) and 15mM 
HEPES (Sigma-Aldrich, USA) at 37°C in a 5% CO2 humidified atmosphere. 
For MCF7 and MDA maintenance medium was supplemented with 5% fetal 
bovine serum (FBS) (Invitrogen, ITA), whereas for BT474 10% FBS was 
added. Cell cultures were routinely checked for mycoplasma with Hoechst 
33258 (Sigma-Aldrich, USA) staining; mycoplasma-negative cells were used 
for experiments. 
 
3.2 Patient samples and blood collection 
Forty-four metastatic breast cancer (MBC) patients, from the Oncology 
department of Azienda Ospedaliera Universitaria Federico II di Napoli were 
enrolled before starting a new line of systemic therapy. Also, blood samples 
from 19 patients were collected after three months of therapy. In addition, 4 
healthy donors (HD) were enrolled in the study. The median age was 61 years 
(range, 39 to 82 years). The most prevalent histotype was ductal (38 out of 44, 
86%) and the most frequent subtype was luminal A (57%). At the time of the 
first blood sampling, all patients had one or more sites of metastases. The 
clinical pathological features of enrolled patients are summarized in Table 1. 
All patients gave their informed consent to participate in the study. Peripheral 
blood (8 to 21 mL) was collected in BD Vacutainer K3EDTA tubes (BD 
Biosciences, San Jose, CA, USA) and processed within 4 hours of blood 
collection. 
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CLINICAL CHARACTERISTIC NUMBER 
TOTAL NUMBER OF SAMPLE 44 
AGE, YEARS  
     MEDIAN 61 
     RANGE 39 to 82 
HISTOLOGY  
     DUCTAL ORIGIN 38 
     LOBULAR ORIGIN 6 
BREAST CANCER SUBTYPE  
     ER-PR-Her2- (TNBC) 3 
     ER+Her2- (ER+) 25 
     Her2+ 16 
NUMBER OF METASTATIC SITES  
     1 16 
     2 16 
     ≥3 12 
SITES OF METASTASIS  
     BONE 21 
     LUNG 7 
     LIVER 17 
     BRAIN 16 
Table1 Clinical characteristic of the patients enrolled in the study. ER, 
Estrogen receptor; PR, Progesterone; TNBC, Triple-negative breast cancer. 
 
3.3 Sample processing for circulating cells isolation 
CTCs enrichment from peripheral blood samples of 14 MBC patients was 
performed by using RosetteSepTM kit (Stem Cell Technologies, CA) according 
to manufacturer’s instructions. RosetteSepTM consists in a tetrameric antibody 
complex that recognizes several antigens present on the surface of unwanted 
cells (i.e. CD45 and glycophorin A, present on leukocytes and red blood cells 
surface, respectively), allowing their depletion from blood sample. Briefly, the 
whole blood volume was incubated with an appropriate volume of 
RosetteSepTM antibody cocktail for 20 minutes, then centrifuged over a Ficoll 
density gradient (Ficoll-Paque Plus, GE Healthcare, Sweden). Unwanted cells 
pellet along with red blood cells, and the buffy coat, containing CTCs, was 
collected and immediately fixed on adhesion slides (ImmunoSelect ®, Squarix 
Biotechnology, USA) for immunofluorescence (IF) experiments. 
Circulating cells from 30 MBC patients were isolated by Ficoll density 
gradient, then the buffy coat, containing the whole peripheral blood 
mononuclear cell (PBMCs) population, was seeded on cover glasses. Five days 
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after seeding, cells were fixed for IF analysis and/or collected for RNA 
extraction. 
 
3.4 PBMCs isolation 
PBMCs were isolated from 2 mL of peripheral blood by Ficoll stratification 
(Ficoll-Paque Plus, GE Healthcare, Sweden). Briefly, whole blood was diluted 
with an equal volume of phosphate buffered saline (PBS) and carefully layered 
over 2mL of Ficoll into a 15 mL conical tube. Samples were centrifuged at 
2100 rpm for 20 minutes at room temperatures. PBMCs were collected, 
washed twice in PBS, and stored at -80°C till RNA extraction.   
 
3.5 Real Time PCR analysis  
Total RNA was isolated from samples and control cells by using TRIzol 
Reagent (Invitrogen, USA) according to the manufacturer’s instructions. RNA 
concentration and purity were determined by measuring the absorbance ratio 
at 260/280 nm in a NanoDrop 2000 (Thermo Scientific, Germany). The 
integrity of RNA was assessed on a standard 1% agarose/formaldehyde gel. 
cDNA was synthesized from 1 µg of total RNA by using the Super Script III 
reverse transcriptase kit (Invitrogen, USA) according to the manufacturer’s 
instructions. Real-time PCR amplification was carried out on a Step One Real-
Time thermocycler (Applied Biosystems, USA) using the iTaq Universal 
SYBR Green Supermix (Bio-Rad, USA). The amplification efficiency of 
primers was assessed by using serial dilutions of cDNA from positive control 
cells.   
Experiments were performed in triplicate for each data point, and the 
expression of housekeeping beta-2-microglobulin gene (B2M Forward: 5’-
GCA GAA TTT GGA ATT CAT CCA AT-3’; Reverse: 5’- CCG AGT GAA 
GAT CCC CTT TTT-3’) was used for normalization.  
Primer sequences are listed in Table 2. 
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Name Sequences 
(5’-3’) 
Product 
size (bp) 
Tm 
 (°C) 
CD45 F ATGGAAGTGCTGCAATGTGTCATT 114 59 
CD45 R  
GAGGCCTACACTTGACATGCATA 
 61 
ERα F TCTTGGACAGGAACCAGGG 71 59 
ERα R TGATGTAGCCAGCAGCATGT  57 
HER2 F CCAGCCTTCGACAACCTCTATT 87 66 
HER2 R TGCCGTAGGTGTCCCTTTG  60 
CK19 F TCAGCGGTATTGAAGCCCAG 117 59 
CK19 R GGTAGGTGGCAATCTCCTGC  61 
Vimentin F GGCTCGTCACCTTCGTGAAT 113 59 
Vimentin R GCAGAGAAATCCTGCTCTCCT  60 
Table2. list of primers. 
 
3.6 Immunofluorescence  
For immunofluorescence analysis circulating cells isolated by RosetteSepTM 
were immediately fixed on adhesion slides (ImmunoSelect ®, Squarix 
Biotechnology, USA), whereas circulating cells isolated by Ficoll density 
gradient were plated on coverslips and fixed 5 days after the seeding. Fixed 
cells were stained at 4°C overnight with either one of the following antibodies: 
anti-ERα (clone 6F11;1:50; Novocastra, UK) anti-HER-2 (clone SP3; 1:50; 
Thermofisher Scientific, USA), anti- EpCAM(C-10; 1:50; Santa Cruz 
Biotechnology, USA), anti-E-cadherin(24E10; 1:50;Cell Signaling 
Technology, USA) anti-CK19 (EPR1579Y; 1:100; Abcam, UK) and anti-
Vimentin (IF01; 1:200;Merck, USA), then treated for 30’ with appropriate 
secondary antibody: goat anti-rabbit IgG Alexa Fluor 594 (1:300; Life 
Technologies, USA) or goat anti-mouse IgG Alexa Fluor 594 (1:100; Life 
Technologies, USA). 
Then, cells were stained with anti-CD45-Alexa 488 conjugated antibody 
(HI30; 1:100; Molecular Probes, USA) and the nuclei were colored with 1:1 
(v/v) Hoechst 33258 (SigmaAldrich, USA)/DRAQ5TM (Abcam, UK) 
solution. All immunofluorescence images were acquired by using a Zeiss 
LSM510 Meta argon/krypton laser-scanning confocal microscope. Results 
were reported as number of cells positive for each marker per milliliters of  
blood.
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4. RESULTS 
 
4.1 RosetteSepTM kit allows the enrichment of mesenchymal cells and 
pauperizes blood samples of adherent cells 
Blood samples from 14 MBC patients were subjected to an antibody-mediated 
depletion procedure (RosetteSepTM, Stem Cell Technologies) for the 
enrichment of nucleated CD45-negative cells (CTCs).  In 8 out of 14 samples 
the phenotype of freshly isolated cells was investigated by 
immunofluorescence. We successfully isolated CTCs in a variable number, 
ranging from 10 to 3243 CTCs /7,5 mL of blood, from 7 out of 8 enrolled 
patients. CTCs were identified as Hoechst/Draq5 + CD45- cells by 
immunofluorescence (figure 4). 
 
 
 
Figure 4. Staining of isolated cells with Hoechst/Draq5 mix (blue) and CD45 
antibody (green); red arrows indicate CTCs (63X objective). 
 
Also, freshly isolated CTCs were probed for the expression of the hormone 
receptor ERα, the growth factor receptor HER2 and EMT markers (CK19, 
Vimentin). Immunofluorescence results were compared with the clinical 
pathological features of the primary tumor. Although all patients had ERα- 
positive primary tumor, we did not isolate any ERα-positive CTCs. In addition, 
isolated cells were negative for HER2 and CK19 expression. Interestingly, 
CTCs from 6 out of 7 samples stained positive for the mesenchymal marker 
Vimentin. Indeed, the 45% of freshly isolated CTCs expressed Vimentin. 
To inquire the adhesion capability of CTCs isolated by RosetteSepTM, we 
seeded freshly CTCs from 6 out of 14 MBC patients on cover glasses. After 
that we looked for nucleated CD45- cells in both the adherent fraction and the 
supernatant by immunofluorescence. CTCs were found only in the adherent 
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fraction of 2 out of 6 samples; These results suggested that RosetteSepTM 
affects CTCs adherence capacity. 
 
4.2 Comparison between PBMCs and adherent cells isolated by Ficoll 
stratification 
The obtained results prompted us to hypothesize that RosetteSepTM pauperizes 
sample of epithelial adherent cells, thus we decided to eliminate the incubation 
step with RosetteSepTM antibody cocktail from our isolation protocol. 
Therefore, the isolation of circulating cells from 6 MBC patients was 
performed by Ficoll density gradient followed by the seeding of PBMCs on 
cover glasses for the enrichment of adherent cells. Also, an aliquot of PBMCs 
from each blood sample was preserved and used for further analysis. To 
investigate which types of cells are enriched by the seeding of free labeled 
PBMCs, the mRNA expression levels of CD45, ERα, HER2, CK19 and 
Vimentin were evaluated by qRT-PCR in both PBMCs and adherent cells. In 
all examined samples, adherent cells expressed lower levels of the leukocyte 
marker CD45 and higher levels of CK19 and Vimentin than PBMCs (figure 
5).  
 
 
 
 
 
Figure 5. Comparison of CD45, CK19 and Vimentin mRNA levels between 
PBMCs and adherent cells from MBC patients. 
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In addition, both PBMCs and adherent cell fraction expressed ERα at 
variable levels among different patients; on average ERα was higher in 
adherent cells than in PBMCs (figure 6). In 5 out of 6 samples HER2 was 
higher in PBMCs than in adherent cells, the mean HER2 mRNA expression 
levels obtained from these samples is shown in figure 6. These results 
suggested that the seeding step eliminated most of contaminating leukocytes 
and allowed the enrichment of adherent cells with both epithelial and 
mesenchymal features.  
 
 
 
 
 
Figure 6. mRNA expression levels of ERα and HER2 in PBMCs and 
adherent cells from MBC patients. 
 
 
4.3 Isolated adherent cells express epithelial and mesenchymal markers  
The seeding of PBMCs after Ficoll stratification eliminated most of leukocytes 
as indicated by the low levels of CD45 in adherent cells respect to PBMCs as 
seen in the experiments reported above. To confirm these findings, adherent 
cells isolated from 30 MBC patients (“before therapy” patients), which have 
started a new line of systemic therapy right after the blood sample withdrawal, 
were analyzed by immunofluorescence for the presence of CD45. 
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Interestingly, among the adherent isolated cells, there were more CD45-than 
CD45+ cells (p< 0,05); on average 9 CD45+ cells/ mL of blood and 48 CD45- 
cell/mL of blood. 
To verify that isolated adherent CD45- cells were CTCs and not cells of 
hematopoietic origin, we proceeded to their characterization. 
To further characterize adherent cells, we stained them with antibody against 
either one of the following antigens: ERα and HER2 (breast cancer specific 
markers), CK19, EpCAM, CK18 and E-cadherin (epithelial markers), CK5 
and Vimentin (mesenchymal markers).  
The number of different cell populations was highly variable between different 
patients. Among examined samples EpCAM+ and E-cadherin+ cells were the 
less representative populations (from 0 to 40 positive cells/ mL of blood). We 
found cells expressing epithelial markers and cells positive for mesenchymal 
markers in a variable number among different patients. The mesenchymal 
markers Vimentin and CK5 were the most expressed (from 19 to 115 positive 
cells/ mL of blood), whereas the most represented epithelial markers were 
CK18 and CK19, with a number of positive cells ranging from 14 to 112/mL 
of blood. Also, ERα positive and HER2 positive cells were observed (from 0 
to 88 ERα+ and HER2+ cells/mL of blood). 
 
4.4 Systemic therapy affects the number of different populations of 
circulating cells 
We wondered whether the phenotype of adherent cells could change after 
therapy. To address this question, we collected blood sample from 18 MBC 
patients after three months of systemic therapy. Circulating cells were isolated 
and the phenotype of adherent cells was investigated by immunofluorescence. 
The results were compared with those obtained from the same patients before 
starting therapy. Importantly, the number of CD45- counted cells/mL of blood 
significantly decreased after therapy of about 62% (p≤0,05). 
Although the number of enrolled patients is not enough to do neither a 
statistical analysis nor a correlation with treatment response, a specific trend 
for each investigated marker seemed to emerge. Besides HER2 positive cells, 
all other cells populations seemed to decrease after therapy (figure 7). In 
media, CK5+, CK18+ and ERα+ cell populations are the most decreased ones 
after treatment, followed by Vimentin+ and CK19+ cells. EpCAM+ and E-
cadherin+ cells were the lowest representative population before therapy; they 
further decreased in samples obtained from treated patients.  
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Figure 7. Bar plots showing the mean fold change in the number of different 
circulating cells populations after therapy. 
 
4.5 Exploiting the utility of PBMCs molecular analysis in MBC management  
Another aim of this study was to exploit the utility of PBMCs analysis in 
monitoring MBC progression and therapy efficacy. To this aim, we examined 
the mRNA expression levels of CD45, ERα, HER2, CK19 and Vimentin in 
PBMCs derived from blood samples of 10 MBC patients and 3 healthy donors. 
Figure 8 shows the average expression for each gene. The expression levels of 
CK19 were significantly higher (p≤ 0,05) in PBMCs from MBC patients than 
from HD. Also, ERα seemed to be more expressed in patients than in healthy 
controls (figure 8). Furthermore, we repeated the analysis on 5 patients after 
three months of systemic therapy; we observed a decrease in ERα mRNA 
levels in 4 out of 5 samples, whereas the mRNA levels of HER2, CK19 and 
Vimentin remained almost the same. ERα expression levels in PBMCs seems 
to discriminate metastatic patients from healthy controls in addition to being 
modulated by systemic treatments. However, to assess the validity of PBMCs 
analysis in the management of MBC disease, a larger number of genes and 
patients needed to be examined.  
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Figure 8. mRNA expression levels in PBMCs from Metastatic breast cancer 
patients (MBC) and healthy donors (HD). * p value ≤ 0,05  
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5. DISCUSSION 
 
Tumor heterogeneity is the main responsible for the failure of therapeutic 
strategies. Breast cancer is highly heterogeneous, and different breast cancer 
subtypes exist. During disease progression cancer generally become more 
heterogeneous; moreover, in the same patient the molecular profile of primary 
and the secondary tumor can be different. Targeted therapies can exert a 
selective pressure on cancer cell clones in favor of specific tumor cell 
subpopulations (Dagogo-Jack and Shaw 2018). All these aspects make cancer 
clinical management a challenge, especially in the metastatic disease. In this 
scenario, the sampling of the tumor at multiple time points to analyze cancer 
cells subpopulations represents an advantageous tool to overcome tumor 
heterogeneity problem and to plan personalized treatments based on time and 
stage-dependent tumor characteristics. 
The analysis of CTCs isolated from peripheral blood samples represents a non-
invasive procedure that could be routinely conducted to monitor “in real time” 
disease progression and therapy efficacy. Despite that, the use of CTCs in the 
clinical practice is still limited because of their rarity in the blood and the lack 
of strategies to efficiently isolate the whole CTCs heterogeneous population. 
Indeed, mainly CTCs isolation methods are epithelial marker-based 
approaches, which fail in detecting circulating cells with mesenchymal 
features. To boost the use of CTCs in the clinical practice, an improvement of 
isolation procedures and an extensive characterization of these cells are 
needed. 
To this aim, we characterized circulating cells isolated through non-epithelial-
based strategies in MBC blood samples. For the enrichment of CTCs from 
MBC blood samples two isolation procedures were tested. In the first part of 
the study we used an antibody-mediated method (RosetteSepTM) for the 
depletion of WBCs and RBCs from MBC patients enrolled prior a new line of 
systemic therapy; this method allowed the isolation of mesenchymal Vimentin 
positive cells, underlining the importance of mesenchymal circulating cells in 
metastatic condition. Neither epithelial (CK19+ cells) nor ERα+ and HER2+ 
cells were found. Moreover, RosetteSepTM seemed to affect circulating cells 
adhesion capability, as suggested by the fact that only isolated cells from 2/6 
samples processed with RosetteSepTM adhered to the cover glasses. 
These results prompted us to eliminate the incubation with RosetteSep 
antibody cocktail and proceeding in the isolation of CTCs by using Ficoll 
density gradient followed by the seeding of PBMCs on cover glasses. 
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This method (Ficoll density gradient followed by the seeding of PBMCs) 
allowed an efficient depletion of contaminating leukocytes and the isolation of 
adherent cells which expressed both epithelial and mesenchymal markers. 
Indeed, the comparison of PBMCs and adherent cells molecular phenotype 
showed that adherent cells expressed lower levels of CD45 and higher levels 
of CK19 and Vimentin than PBMCs. Also, the depletion of WBCs from the 
samples was confirmed by the low number of CD45+ cells respect to CD45- 
cells (putative CTCs) investigated by immunofluorescence. 
In addition, immunofluorescence experiments revealed that among adherent 
isolated circulating cells there were cells positive for epithelial markers (CK19, 
CK18) and cells positive for mesenchymal markers (CK5, Vimentin). These 
results are consistent with the crucial role of EMT in the spreading of 
metastatic disease. Mesenchymal CTCs have already been described in breast 
cancer, and it seems that they are associated with disease progression (Yu, 
Bardia, Ben S Wittner, et al. 2013).  Moreover recent evidence suggests that 
both epithelial and mesenchymal features are needed for metastasis formation: 
mesenchymal phenotype confers migrative and invasive properties, whereas 
epithelial characteristics are required to proliferate at secondary site (Mitra et 
al. 2015). 
Currently, the isolation of CTCs relies on EpCAM-based methods; however, 
EpCAM is downregulated during tumor dissemination due to EMT process. 
Hence, EpCAM-based isolation approaches underestimate CTCs number, 
missing critical subpopulation of circulating cancer cells (Hyun et al. 2016).  
In agreement with this assumption, in our analysis EpCAM+ and E-cadherin+ 
cells were the less representative populations in adherent isolated circulating 
cells. These findings underlined that an improvement of CTCs isolation 
strategies to study epithelial-mesenchymal transitioned CTCs is indispensable. 
Recently, it has been recognized the importance of monitoring ERα and HER2 
status also in more advanced stages of breast cancer. In our study, both 
immunofluorescence and qRT-PCR experiments detected the presence of 
ERα+ and HER2+ cells in the adherent cell fractions isolated from MBC blood 
samples. In particular, qRT-PCR analysis showed that ERα was expressed at a 
variable level among patients, whereas HER2 was higher in PBMCs than in 
adherent cells, probably because of natural killer cells/granulocytes, which 
may be eliminated by the seeding. Indeed, it has been documented that natural 
killer cells/granulocytes are the main source of HER2 in PBMCs (You et al. 
2008). Consistent with literature data (Onstenk et al. 2015), our experiments 
demonstrated that ERα and HER2 expression in CTCs differs from ERα and 
HER2 clinical pathological features of the same patient’s primary tumor. 
Discrepancy between primary tumor and CTCs profiles have been proposed as 
a prognostic factor in MBC. In addition,  defining the role of ERα+ and HER2+ 
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CTCs could be useful to identify metastatic patients that will benefit from 
receiving specific targeted therapies (Onstenk et al. 2015; Jordan et al. 2016). 
In our study we also characterized adherent circulating cells isolated from 
MBC patients who underwent three months of systemic therapy, to exploit 
changes eventually occurred in CTCs phenotype. The number of CD45- cells 
significantly decreased in post therapy samples, also the number of different 
examined populations of circulating cells changed.  A considerably decrease 
was registered for CK5+, CK18+ and ERα+ cell populations; Vimentin+ and 
CK19+ cells slightly diminished after therapy. Furthermore, EpCAM+ and E-
cadherin+ cells, which were the lowest representative population before 
therapy, further decreased in samples obtained from treated patients. HER2+ 
population only did not decrease after therapy. We are planning to validate our 
results in a larger cohort of patients in order to assess correlations between 
CTCs phenotype and treatment response. The phenotyping of CTCs 
subpopulations under therapeutic pressure would give a great contribution in 
the clinical management of cancer in general. It has been demonstrated that in 
small cell lung cancer patients the increase of  Vimentin+ CTCs number after 
one-treatment cycle correlates with low OS (Messaritakis et al. 2017). Also, a 
study conducted by Angelaki and collaborators on TNBC patients 
demonstrated that the presence of HER2+ CTCs after adjuvant chemotherapy 
is indicative for progression disease (Agelaki et al. 2017). The recent 
increasing interest in CTC-phenotypization is underlined by the fact that large 
phase III study, named DETECT III, is ongoing with the aim to exploit utility 
of CTC phenotype in guiding therapeutic decision. The study will compare 
standard therapy alone versus standard therapy plus Lapatinib in patients with 
initially HER2- MBC and HER2+ CTCs. 
Our results together with literatures data support the need of a wide 
characterization of CTCs both before and at different time points during 
therapy to improve their isolation and to introduce CTCs-based clinical 
therapeutic decisions. 
Despite recent advances in isolation method an efficient exhaustive study of 
CTCs remains challenging; on the contrary, PBMCs collection is well 
established and routinely performable. For these reasons the possibility to 
predict disease progression and therapy response based on PBMCs molecular 
profile needs to be exploited.  To this aim, we examined the mRNA expression 
levels of CD45, ERα, HER2, CK19 and Vimentin in PBMCs derived from 
blood samples of 10 MBC patients and 3 HD. Interestingly, CK19 was 
significantly more expressed in MBC-PBMCs than in HD-PBMCs.  To note, 
CK19 has been the most extensively used markers for the detection of CTCs 
in the blood of cancer patients. Moreover, the detection of CK19 mRNA before 
the initiation of adjuvant chemotherapy has been recognized as an independent 
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prognostic factor for disease recurrence and decreased survival in patients with 
early breast cancer (Stathopoulou et al. 2002; Xenidis et al. 2006). 
In our study ERα seemed to be more expressed in patients than in healthy 
controls. In addition, the analysis on 5 patients after three months of systemic 
therapy revealed a decrease in ERα mRNA levels in 4 out of 5 samples. ERα 
expression levels in PBMCs seems to discriminate metastatic patients from 
healthy controls in addition to being modulated by systemic treatments. 
Recently, a gene expression profile study has demonstrated that ERα gene is 
significantly differentially expressed in MBC respect to HD (Hensler et al. 
2016).   The identification of a PBMCs genes panel revealing the presence of 
CTCs (CTCS signature) in the blood of cancer patients would help in the 
management of MBC disease.
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6. CONCLUSION 
 
In this study we established a label-free method for the isolation and 
characterization of circulating cells in MBC. This method, consisting in Ficoll 
density gradient centrifugation followed by the seeding of label free PBMCs 
on cover glasses, allowed the depletion of most contaminating leukocytes and 
the enrichment of adherent cells expressing both epithelial and mesenchymal 
markers, overcoming the loss of mesenchymal CTCs that occurs by using 
commonly epithelial-based isolation strategies. Adherent cells were also 
characterized for the expression of different markers (hormone receptor, 
growth factor and EMT markers), revealing the presence of different 
circulating cell subpopulations. These subpopulations were investigated also 
in post therapy samples. So far, the number of enrolled patients was not enough 
to do any correlation with clinical features and patients’ outcome. Despite that, 
our results, together with literature data, support the idea that CTCs 
phenotyping both before and at different time points during therapy is 
necessary for the improvement of CTCs isolation and for the designing of 
CTCs-based cancer therapies. Furthermore, this study exploited the possibility 
to use PBMCs molecular profile as a surrogate of CTCs signature for MBC 
clinical management. 
In conclusion, the analysis of CTCs remains a promising tool in cancer 
management that needs to be improved to obtain “ad hoc” personalized 
therapies to contrast the tumor heterogeneity underlying the progression of 
disease.
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